
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with potential in ophthalmology for $2.2 billion
On Nov. 16, 2026, Johnson & Johnson announced it has entered into a definitive agreement to acquire Ollin Biosciences a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences to support the Phase 3 clinical advancement of OLN324, contingent upon acquisition close.
With this agreement, Johnson & Johnson would add to its pipeline OLN324, an investigational bispecific antibody designed to target two key pathways in retinal diseases, vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). OLN324 is a next-generation antibody with high Ang2 potency and a small protein format (minibody) that could enable improved control of retinal fluid. It is being developed for conditions including wet age-related macular degeneration (AMD) and diabetic macular edema, which together affect more than 40 million people worldwide and are leading causes of vision loss.
Johnson & Johnson’s combination of scientific, development and commercial capabilities position the Company to advance OLN324 and build on Ollin’s promising science. The proposed acquisition would strengthen Johnson & Johnson’s leadership in ophthalmology and its commitment to preserve, restore, and enhance vision for millions of people worldwide.
Tags:
Source: Johnson & Johnson
Credit:
